Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86917 trials found · Page 78 of 4346
-
New strategy aims to stop blood cancer from returning after transplant
Disease control Recruiting nowBackground: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high. Researchers want to see if giving the transplant recipient an infusion of lymphocytes (a type of white blood cell) from their transp…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC
-
Scientists test re-engineered immune cells to stop Myeloma's return
Disease control OngoingThe purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC
-
Breakthrough drug trial offers hope for devastating rare disease with no current treatment
Disease control Recruiting nowBackground: Proteus syndrome is a rare overgrowth disorder. Most people begin to have symptoms between 6 months and 2 years of age. There are very few living adults with this disease. There is also no known treatment for it. Researchers want to see if a new drug can slow down or…
Phase: PHASE2 • Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Can a Vaccine-Like shot save Insulin-Making cells in type 1 diabetes?
Disease control OngoingThe objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters…
Phase: PHASE3 • Sponsor: Diamyd Medical AB • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
New drug targets deadly immune storm in rare disease
Disease control Recruiting nowHemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (e…
Phase: PHASE2, PHASE3 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
New drug combo shows promise in fighting tough lung cancer
Disease control OngoingThis study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Magnetic pulses to the brain: new hope for the toughest OCD cases
Disease control Recruiting nowTETRO is a multi-center placebo-controlled double-blind randomized controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months in 250 adult (18 years and older) OCD patients who show no/insufficient response to ERP, aiming to establish the cost-eff…
Phase: PHASE3 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
New hope for Tough-to-Treat breast cancer: targeted drug challenges chemo in major trial
Disease control OngoingThis is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 06, 2026 14:06 UTC
-
New antibody may boost stem cell transplant success for blood disorders
Disease control OngoingBackground: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD. Treatments that improve survival rates are needed. Objective: To f…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
Two-step surgery may prevent ovarian cancer without early menopause
Prevention Recruiting nowThis is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Apr 26, 2026 20:02 UTC
-
New drug aims to stop rare disease that turns muscles into bone
Disease control Recruiting nowThis Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
One blood test for 20 cancers: major study aims to catch cancer early
Diagnosis Recruiting nowThis is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometria…
Sponsor: Adela, Inc • Aim: Diagnosis
Last updated Apr 09, 2026 19:31 UTC
-
Scientists re-engineer Patients' own immune cells to hunt ovarian cancer
Disease control Recruiting nowThe purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning ch…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Breakthrough trial tests Life-Saving TB treatment for most vulnerable HIV patients
Disease control CompletedDATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 ce…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New hope for Tough-to-Treat colon cancer: targeted combo enters final testing
Disease control OngoingThe aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipir…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Lab-Grown heart cells injected into failing hearts: a new hope?
Disease control OngoingThe purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.
Phase: PHASE1, PHASE2 • Sponsor: Heartseed Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Could whole blood save more lives in trauma emergencies?
Disease control CompletedOpen label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to standard of care resuscitation in patients at risk of hemorrhagic shock and to appropria…
Phase: PHASE3 • Sponsor: Jason Sperry • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Immunotherapy shows promise in Tough-to-Treat uterine cancer
Disease control OngoingPhase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.
Phase: PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
New hope for Tough-to-Treat stomach tumors in major trial
Disease control OngoingThis is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be …
Phase: PHASE3 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Heated chemo bath tested as new weapon against tough ovarian cancer
Disease control OngoingPlatinum-resistant recurrent epithelial ovarian cancer randomizing with or without cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC): KOV-02R, RECOVER
Phase: PHASE3 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC